NCT00000617

Brief Summary

To determine whether treatment with azithromycin decreases the rate of coronary heart disease events among patients with stable documented coronary artery disease.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Sep 1998

Longer than P75 for phase_3

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1998

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

October 27, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 28, 1999

Completed
6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2005

Completed
Last Updated

November 7, 2016

Status Verified

May 1, 2005

First QC Date

October 27, 1999

Last Update Submit

November 4, 2016

Conditions

Coronary DiseaseHeart DiseasesMyocardial InfarctionCardiovascular Diseases

Interventions

azithromycinDRUG

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Men and women over the age of 18 who have stable, documented coronary artery disease (CAD). Evidence of CAD was by any one of: history of MI; greater than 50% stenosis in any coronary artery; or history of coronary revascularization procedure.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Related Publications (3)

  • Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis. 2000 Jun;181 Suppl 3:S579-81. doi: 10.1086/315628.

    PMID: 10839763BACKGROUND

  • Anderson JL. Infection, antibiotics, and atherothrombosis--end of the road or new beginnings? N Engl J Med. 2005 Apr 21;352(16):1706-9. doi: 10.1056/NEJMe058019. No abstract available.

    PMID: 15843674BACKGROUND

  • Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005 Apr 21;352(16):1637-45. doi: 10.1056/NEJMoa043526.

    PMID: 15843666BACKGROUND

MeSH Terms

Conditions

Coronary DiseaseHeart DiseasesMyocardial InfarctionCardiovascular Diseases

Interventions

Azithromycin

Condition Hierarchy (Ancestors)

Myocardial IschemiaVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

ErythromycinMacrolidesPolyketidesLactonesOrganic Chemicals

Study Officials

  • J. Grayston

    University of Washington

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
PREVENTION
Sponsor Type
NIH

Study Record Dates

First Submitted

October 27, 1999

First Posted

October 28, 1999

Study Start

September 1, 1998

Study Completion

November 1, 2005

Last Updated

November 7, 2016

Record last verified: 2005-05